AbCellera Biologics Inc [ABCL] stock is trading at $2.77, down -0.36%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABCL shares have gain 1.47% over the last week, with a monthly amount drifted -29.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
AbCellera Biologics Inc [NASDAQ: ABCL] stock has seen the most recent analyst activity on February 22, 2024, when The Benchmark Company upgraded its rating to a Buy but kept the price target unchanged to $9 for it. Previously, KeyBanc Capital Markets started tracking the stock with Overweight rating on December 05, 2023, and set its price target to $6. On November 06, 2023, downgrade downgraded it’s rating to Hold. Cowen initiated its recommendation with a Outperform. Goldman started tracking with a Buy rating for this stock on December 15, 2022, and assigned it a price target of $30. In a note dated November 16, 2022, Truist initiated an Buy rating and provided a target price of $29 on this stock.
AbCellera Biologics Inc [ABCL] stock has fluctuated between $2.71 and $8.05 over the past year. Currently, Wall Street analysts expect the stock to reach $23.6 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $2.77 at the most recent close of the market. An investor can expect a potential return of 751.99% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
AbCellera Biologics Inc [NASDAQ:ABCL] reported sales of 35.79M for the trailing twelve months, which represents a drop of -18.36%. Gross Profit Margin for this corporation currently stands at 0.15% with Operating Profit Margin at -6.35%, Pretax Profit Margin comes in at -4.71%, and Net Profit Margin reading is -4.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.13 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.71 points at the first support level, and at 2.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.81, and for the 2nd resistance point, it is at 2.86.
Ratios To Look Out For
For context, AbCellera Biologics Inc’s Current Ratio is 7.76. On the other hand, the Quick Ratio is 7.75, and the Cash Ratio is 1.42. Considering the valuation of this stock, the price to sales ratio is 22.76, the price to book ratio is 0.72.
